Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/26/2014)... RADNOR, Pa. , Nov. 26, 2014 ... dedicated to the development of innovative transdermal synthetic cannabinoid ... the Piper Jaffray 26th Annual Healthcare Conference 2014. The ... the New York Palace in New York ... , will present at 4:50 pm on Tuesday, December ...
(Date:11/26/2014)... -- According to the new research ... Battery, Pneumatic), by Product (Drill, Saw, Stapler, Reamer, ... (Orthopedic, ENT, Oral, Thoracic, Neurology) - Global Forecasts ... Instruments Market is estimated to be worth around ... expected to grow at a moderate CAGR during ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
... 4, 2011 Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... North America beyond physician offices and outpatient clinics with the ... and reference laboratories. The new line is expected to be ... regulatory approval and other requirements. Roche Diagnostics ...
... CLEMENTE, Calif., Oct. 4, 2011 ReShape Medical®, Inc. ... and chief executive officer.  Interim CEO, Ken Charhut, will ... chairman of the board for ReShape Medical.   ... and CEO of Luminous Medical, Inc., an innovative glucose ...
Cached Medicine Technology:Roche to Expand Coagulation Testing Portfolio, Develop New Systems for Diagnostic Laboratories in US and Canada by 2014 2ReShape Medical Names Richard Thompson President and Chief Executive Officer 2
(Date:11/27/2014)... November 27, 2014 Absolute PhysioCare ... recently announced that its personalized treatment plans, highly ... can help victims of sports injuries reach pre-injury ... or patellofemoral pain syndrome, Absolute Physio has the ... jumper’s knee, ACL tears, meniscal injuries, groin strain ...
(Date:11/27/2014)... November 27, 2014 Cambrionix Ltd today announced ... Fast 50, a ranking of the 50 fastest-growing technology companies ... growth over the last five years. Cambrionix Ltd grew ... ranked first in the region of Cambridgeshire and East and ... Director Says:, “This award is recognition of the hard work ...
(Date:11/27/2014)... An inventor from Buffalo, N.Y., knows ... life, and she wants to lessen its impact. "After ... decided that there needed to be a way to ... to use and producible in design variations, the End ... areas throughout the day. It avoids bad odors, as ...
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... 2014 (HealthDay News) -- Thanksgiving meals can pose a ... diet, an expert says. Many traditional Thanksgiving dishes ... sauce -- are gluten-free, but "when it comes to ... be considered," Dr. Anca Safta, director of the Gluten ... Medical Center in North Carolina, said in a center ...
Breaking Medicine News(10 mins):Health News:Coquitlam Physiotherapy Clinic Now Helps Clients Reach Pre-Injury State 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2
... to prescription painkillers are more likely to succeed ... medication buprenorphine-naloxone (Suboxone), report McLean Hospital and Harvard ... the Archives of General Psychiatry. ... for Prescription Opioid Dependence," is the first large-scale ...
... A microsurgical procedure that has lost some ground ... role in the management of selected neurovascular disorders, according ... performs the procedure. "Though its indications are ... make all the difference for certain patients who have ...
... , MONDAY, Nov. 7 (HealthDay News) -- ... school athletes, a new study indicates. In neuromuscular ... progresses to focusing on muscles and motions used in ... and almost 1,500 female basketball and soccer players from ...
... by 2007 annual sales of the cards were at 85,000. America ... in the U.S. over the age of 80 is expected to ... how well they live. The new book, Aging Our Way ... of 30 eldersranging in age from 85 to 102living at home ...
... Go Fish with 3,000 cards. Scientists at Rochester Institute ... game with higher stakes. Instead of cards, they are matching ... body. Their research could lead to drugs that target proteins ... diseases. The three-year study is funded by a $417,000 ...
... who believe a rule or restriction is absolute are more likely ... wiggle room, according to a new study. The findings may ... Arab Spring uprisings, according to the authors of the study to ... Science . In the study, participants read articles that ...
Cached Medicine News:Health News:Suboxone is most effective in treating painkiller addiction 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 2Health News:University Hospitals Case Medical Center neurosurgeons champion brain bypass in select patients 3Health News:Specialized Warm-Up May Reduce Girls' Knee Injuries 2Health News:What can we learn from America's fastest growing and least understood age group? 2Health News:Opening the data bank -- scientists try to match new protein structures 2Health News:People Seem More Likely to Follow Rules They Can't Beat 2
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Thumb Spica Splint provides effective long-term ... custom fit. Adjustable radial and palmar ... for Gamekeper's thumb, de Quervain's, scaphoid ... closure straps.,FormFit™ Splints offer superior fit ...
Qualcare™ Thumb Spica...
... QuickCast® Cast-like splints Slip on, ... and QuickCast conforms to fit. ... Reheat to adjust and reposition. ... with a temperature-sensitive polymer Straps ...
Medicine Products: